Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the common sleeping disorder.
Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...
Eli Lilly (LLY) announced today that its blockbuster weight-loss drug Zepbound was approved by the U.S. Food and Drug ...
Although the GLP-1 drug Zepbound has been shown to be effective in promoting weight loss, availability and price have ...
Eli Lilly said on Wednesday patients ... JAMA Internal Medicine earlier this year showed Zepbound led to faster and greater weight loss than Wegovy. U.S.-based Lilly and Danish rival Novo ...
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback